The Fibrolamellar variant of Hepatocellular Carcinoma (FLHCC) is a rare form of liver cancer that presents in the 3 rd decade of life, is rarely associated with cirrhosis or chronic Hepatitis B/C virus infection, and usually presents with normal serum alpha-fetoprotein (AFP) levels. FLHCC presenting during pregnancy is extremely rare, with only 4 cases reported. We present a case of FLHCC in pregnancy and discuss the dilemmas in management. A 26 year-old primigravida, 26 weeks of gestation presented with a month's history of obstructive jaundice secondary. Investigations revealed a mass in the left lateral segment of the liver with extension down the left hepatic duct into the common bile duct. Following an emergency caesarean section at 31 weeks, she underwent a left hepatectomy with extrahepatic bile duct excision. The postoperative course was uneventful. Histopathology showed FLHCC. In conclusion, liver tumors presenting during pregnancy should be managed in a multidisciplinary setup with facilities for neonatal intensive care. Management depends on the presumed pathology, period of gestation and family preferences. 
INTRODUCTION
The fibrolamellar variant of Hepatocellular Carcinoma (FLHCC) accounts for 1% of all primary liver cancers. 1 Unlike typical hepatocellular Carcinoma (HCC), FHLCC occurs predominantly in the 3 rd decade of life, is not associated with chronic Hepatitis B/C virus infection, and 90% exhibit normal serum alpha-fetoprotein (AFP) levels. 1 FLHCC presenting during pregnancy is extremely rare. 2 We report a case of FLHCC presenting during the second trimester of pregnancy and review the relevant literature.
CASE
A 26 year-old primigravida, 26 weeks of gestation presented with a month long history suggestive of obstructive jaundice. There was no history of use of hormonal contraceptive pills. Liver Function Tests showed an obstructive picture, a negative viral serology, a serum AFP level of 195.8 IU/ml (normal ＜5.8 IU/ml), and a cancer antigen level (CA) of 19.9-64.8 U/ml (normal ＜34 U/ml).
Magnetic Resonance Imaging (MRI) showed a 6.4 cm×4.4
cm irregular lesion in segments II and III of the liver with contiguous extension into the common bile duct (CBD) (Fig. 1) . The tumor was hyperintense on T2-and hypointense on T1-weighted images.
With a presumptive diagnosis of HCC/hepatocholangiocarcinoma, options offered included continuation of pregnancy to 28 weeks and subsequent surgery or immediate termination of pregnancy with surgery.
Due to financial constraints, the family made an informed decision to continue the pregnancy to 32 weeks. A right-sided percutaneous transhepatic biliary drainage (PTBD) was performed. She returned three weeks later A subsequent computed tomography (CT) scan confirmed the MRI findings but also suggested that the tumor might be extending up to the suprapancreatic margin of the CBD (Fig. 2) . Intraoperatively, the tumor was found to be confined to segments II and III of the liver ( MRI is usually confirmatory and biopsy rarely essential.
Patients with a history of resected liver malignancy, cirrhotics, or chronic Hepatitis B/C should have a liver ultrasound during the routine fetal screening to rule out recurrence.
Our case is unique in that FLHCC presented as obstructive jaundice during pregnancy. FLHCC should be considered as a differential diagnosis in non-cirrhotic, pregnant patients presenting with obstructive jaundice and a liver lesion. Treatment of liver tumors during pregnancy must be individualized based on the diagnosis a patient and family preferences.
